All In Biotech

Drug Trial Radar · NCT00886470

ST266 Versus Standard Care In Treating Partial Thickness Burns

Phase I/II Randomized Blinded Safety, Dose-determining Efficacy Trial Comparing Amnion-derived Cellular Cytokine Solution in 3 Different Regimens With Standard Care 0.9% Sodium Chloride in the Topical Treatment of Partial-thickness Burns

Last checked: Nov 19, 2026Latest source record: May 15, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

16

Actual

Start

Jun 2009

Primary completion

Mar 2010

Study completion Mar 2010

Sponsor

Sponsor type
Industry
First posted
Apr 23, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective of this protocol is to perform a safety and dose-determination efficacy clinical trial in patients having a degree of partial-thickness burn wounds. The trial will be a prospectively randomized and double-blind trial of ST266 compared with standardized care using 0.9% NaCl (normal saline) solution in the same three treatment regimens.

Conditions

  • Burns

Interventions

  • ST266Biological

    ST266 is a clear liquid containing more than 200 proteins, cytokines, and growth factors in solution. Patients will be treated for 21 days unless both wounds have healed prior to 21 days, at which time a punch biopsy of the epithelialized area of each wound will be performed. A study evaluation visit for assessment of the biopsy site will occur on day 28 or within 7 days of the punch biopsies, whichever occurs first. Six months after the punch biopsy, the patient will return to the burn center for a final examination and photographs of the study wounds.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The primary endpoint will be the percentage of each wound that has epithelialized during the 21-day treatment period comparing the ST266-treated wound with the saline-treated wound.Time frame: 21 days

Locations

14 sites in 1 country. Site status is shown where the registry gives one.

  • University of South Alabama Dept. of Surgery

    Mobile, Alabama

  • LAC - USC Medical Center

    Los Angeles, California

  • Shands Burn Center at the University of Florida

    Gainesville, Florida

  • University of South Florida / Tampa General Hospital

    Tampa, Florida

  • Loyola University Medical Center

    Maywood, Illinois

  • University of Kentucky Chandler Medical Center

    Lexington, Kentucky

  • Johns Hopkins Burn Center

    Baltimore, Maryland

  • Brigham and Women's Hospital

    Boston, Massachusetts

  • University of Missouri Health Care

    Columbia, Missouri

  • Acute & Critical Care Surgery Barnes Jewish Hospital, Washington University Medical Center

    St Louis, Missouri

  • University of Rochester

    Rochester, New York

  • MetroHealth Medical Center

    Cleveland, Ohio

  • Western Pennsylvania Hospital

    Pittsburgh, Pennsylvania

  • John S. Dunn Sr. Burn Center

    Houston, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.